哈尔滨科信必成医药科技发展

Harbin Cosci-Med Pharmaceutical Technology Development is a Chinese pharmaceutical research and development organization specializing in the formulation and industrialization of oral solid dosage forms. As a key entity within the Cosci-Med group, the company focuses on advanced drug delivery systems, including sustained-release, controlled-release, and rapid-release technologies, with a particular emphasis on pediatric formulations and orphan drugs. Harbin Cosci-Med provides comprehensive, one-stop R&D services from formulation design and quality standard research to pilot-scale testing and technology transfer. Notably, the company successfully developed China's first Class 2.2 improved new drug, Ambroxol Hydrochloride Direct-to-Mouth Granules, which has been approved for commercial production.